Drug intelligence / Profile preview

lemzoparlimab + daratumumab + dexamethasone

Development stage: Unknown
Lead developer: I-MAB
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous (lemzoparlimab, Daratumumab), Oral (dexamethasone), Intravenous (daratumumab Also Available As Subcutaneous Formulation, But Primarily Iv In Combinations)

Overview

**lemzoparlimab + daratumumab + dexamethasone** is a combination regimen under investigation for the treatment of relapsed/refractory multiple myeloma and potentially other malignancies. - **Lemzoparlimab** is a humanized monoclonal antibody targeting CD47, an immune checkpoint that delivers a "do not eat me" signal, thereby enhancing macrophage-mediated phagocytosis of tumor cells. - **Daratumumab** is a monoclonal antibody targeting CD38 on plasma cells, leading to direct cytotoxicity, immune-mediated killing, and modulation of the tumor microenvironment. - **Dexamethasone** is a synthetic glucocorticoid that provides anti-inflammatory activity and can induce apoptosis in cancer cells. This multi-agent combination is designed to provide synergistic anti-myeloma effects by targeting both tumor cell immune evasion mechanisms and directly depleting malignant plasma cells.

Brand names: Darzalex (daratumumab)None for lemzoparlimab + daratumumab + dexamethasone as a fixed combination

Targets

CD38 (Cluster of Differentiation 38)CD47 (Cluster of Differentiation 47)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on lemzoparlimab + daratumumab + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lemzoparlimab + daratumumab + dexamethasone.

Explore the full profile